Pharmacokinetics of mitiperstat in participants with hepatic impairment

Trial Identifier: D6581C00002
Sponsor: AstraZeneca
NCTID:: NCT05751759
Start Date: March 2023
Primary Completion Date: November 2024
Study Completion Date: November 2024
Condition: Liver, Pancreas & Gallbladder - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, CA Rialto, CA, US, 92377
US, FL Hialeah, FL, US, 33016
US, FL Orlando, FL, US, 32808
US, OH Canton, OH, US, 44718
US, TX San Antonio, TX, US, 78215